Hans Van Der Eecken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hans Van Der Eecken has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Alexander Giesen
Dep. of Urology, University Hospitals Leuven, Belgium
1 shared publicationBram Vansevenant
Dep. of Urology, University Hospitals Leuven, Belgium
1 shared publication- Charlien Berghen
Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium
1 shared publication Dieter Ost
Dep. of Urology, AZ Sint-Blasius Dendermonde, Belgium
1 shared publicationEduard Roussel
Dep. of Urology, University Hospitals Leuven, Belgium
1 shared publicationFilip Ameye
Dep. of Urology, AZ Maria Middelares Gent, Belgium
1 shared publication
Latest Publications
- Open Access
The Use of Soy Isoflavones in the Treatment of Prostate Cancer: A Focus on the Cellular Effects
A possible link between diet and cancer has long been considered, with growing interest in phytochemicals. Soy isoflavones have been associated with a reduced risk of prostate cancer in Asian populations. Of the soy isoflavones, genistein and daidzein, in particular, have been studied, but recently, equol as a derivative has gained interest because it is more biologically potent. Different mechanisms of action have already been studied for the different isoflavones in multiple conditions, such as breast, gastrointestinal, and urogenital cancers. Many of these mechanisms of action could also be demonstrated in the prostate, both in vitro and in vivo. This review focuses on the known mechanisms of action at the cellular level and compares them between genistein, daidzein, and equol. These include androgen- and estrogen-mediated pathways, regulation of the cell cycle and cell proliferation, apoptosis, angiogenesis, and metastasis. In addition, antioxidant and anti-inflammatory effects and epigenetics are addressed.
Open AccessThe Use of Soy Isoflavones in the Treatment of Prostate Cancer: A Focus on the Cellular Effects
A possible link between diet and cancer has long been considered, with growing interest in phytochemicals. Soy isoflavones have been associated with a reduced risk of prostate cancer in Asian populations. Of the soy isoflavones, genistein and daidzein, in particular, have been studied, but recently, equol as a derivative has gained interest because it is more biologically potent. Different mechanisms of action have already been studied for the different isoflavones in multiple conditions, such as breast, gastrointestinal, and urogenital cancers. Many of these mechanisms of action could also be demonstrated in the prostate, both in vitro and in vivo. This review focuses on the known mechanisms of action at the cellular level and compares them between genistein, daidzein, and equol. These include androgen- and estrogen-mediated pathways, regulation of the cell cycle and cell proliferation, apoptosis, angiogenesis, and metastasis. In addition, antioxidant and anti-inflammatory effects and epigenetics are addressed.